Biotechnology company Chiron announced the launch Thursday of human clinical trials of its two-part experimental HIV vaccine, the Los Angeles Times reports. Participants in the trials will first receive a DNA-based vaccine containing two key HIV proteins to prime the immune system into recognizing the invading virus and a booster shot aimed at further stimulating an immune response. An initial two-year safety trial will involve 168 HIV-negative volunteers in St. Louis, Seattle, and Nashville. Additional efficacy tests will be conducted after the safety study.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved















